Affimed N.V. (AFMD) - Cash Funds Calculated per Share

Affimed is creating a safe alternative to chemotherapy by utilizing the ROCK platform to activate NK cells against lymphomas. Affimed aims to capture market share in the innate immunity sector before the products of corporate behemoths are released. Cash per share has reached 0.00, confirming the company's status as a scientific leader in the field of precision cancer immunotherapy.
Comprehensive metric breakdowns and analytics for Affimed Therapeutics (AFMD)

Conservative capital demands maximum liquidity transparency to assess business resilience. This metric determines the share of cash reserves per security, measuring the asset's actual defensive cushion. For Affimed (AFMD), this resource is generated through royalties and upfront payments from partners via the ROCK platform. Analyzing the cash per share allows for an assessment of the autonomy of immunotherapy development. The trend of this indicator determines the balance between financial security and potential yield.